FridayAug 25, 2017 9:23 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Continues to Deliver Results with its Patented Technology

19 patent applications filed in the United States and internationally (under the Patent Cooperation Treaty), with national filings in 44 countries Collaborative research and development agreement with Canada’s National Research Council to investigate opportunities associated with bioavailability enhancement of certain compounds, including those in cannabinoids, vitamins, NSAIDs and nicotine Out-licenses its patented technology to third party partners, with several deals signed or pending When Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) researchers tackled the issue facing consumers of edible cannabinoids – poor absorption of the product’s bioactive compounds by the body’s gastrointestinal tract – an important statement led the way:…

Continue Reading

ThursdayAug 24, 2017 3:22 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Licensed to Grow Cannabis by Feds in Canada

An early mover in the Canadian cannabis space Serving Canada’s most populous province New funding deal signed for $15 million at $2.25 per share As befits its status as a first mover in the Canadian cannabis space, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) is racing ahead with plans to supply the medical marijuana needs of Canada’s most populous province. Construction plans at its Kimmett facility in the third quarter of 2017 remain on schedule, and the previously announced plans for a 71,000 square foot phase 1 project have been expanded to 100,000 square feet. The company recently signed a…

Continue Reading

FridayAug 04, 2017 3:24 pm

7 Company Updates from this Week to Review

The last week has been quite busy for the global marijuana industry as companies continued to execute and work to create value for shareholders. Although the marijuana industry is comprised of some incredible companies, investors must be selective and focus on the real players. Today we have highlighted 7 developments that marijuana stock investors need to know about. Insys: Second Quarter Revenue Drops 38% Nasdaq-traded Insys Therapeutics (INSY) reported its second quarter financial results today and recorded a 38% drop in revenue when compared to the same quarter last year. Although this biotech cannabis stock has continued to execute, the…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050